A single pill low-dose combination therapy could reduce the risk of recurrent stroke by almost 40%, trial results show. 

GMRx2, developed by biopharmaceutical company George Medicines, reduced recurrent stroke risk in patients with previous intracerebral haemorrhage (ICH) by 39% compared to placebo, according to results published in the New England Journal of Medicine. 

The pill, a combination therapy of telmisartan, amlodipine and indapamide, was evaluated in an international study involving 1,670 participants with a recent ICH event who were on standard of care treatment. During an average duration of follow-up of three years, stroke occurred in 4.6% of patients receiving GMRx2 compared to 7.4% in the placebo group. 

The GMRx2 group also achieved better blood pressure (BP) control, with mean systolic blood pressure levels 9mmHg lower than the placebo group, a result maintained during the course of the study.  

Around 100 million people worldwide have experienced a stroke, with ICH recognised as the most serious form. Twelve million new cases occur each year, with recurrent strokes representing between 25-30% of all cases.  

“For patients who have survived an intracerebral haemorrhage, the risk of a second stroke remains high,” said Dr Kevin Sheth, Professor of Neurology and Neurosurgery, Vice Chair for Clinical and Translational Research, and Director of the Center for Brain & Mind Health at Yale School of Medicine. 

“This trial showed that a structured, intensive blood pressure-lowering approach using a single-pill triple combination can translate into meaningful reductions in recurrent stroke risk. This finding has the potential to directly address the long-standing challenges of under-treatment, adherence issues prominent for this patient population, and therapeutic inertia that stand in the way of a safe and effective preventative treatment that can improve outcomes for patients.”